AIMS: Increased angiogenesis leads to invasion in cervical cancer. Vascular endothelial growth factors (VEGFs) are involved in angiogenesis, but molecular links to the most important aetiological agent, human papillomavirus (HPV), need clarifying. MATERIAL/ METHODS: Archival samples-150 squamous cell carcinomas (SCCs) and 152 cervical intraepithelial neoplasia (CIN) lesions-were examined immunohistochemically for anti-VEGF-C antibody and for HPV by polymerase chain reaction (PCR). Follow up data were available for all SCC cases, and 67 CIN lesions were monitored with serial PCR to assess HPV clearance/persistence after treatment. RESULTS: High risk (HR) HPV types were closely associated with CIN (odds ratio, 19.12; 95% confidence interval, 2.31 to 157.81) and SCC (27.25; 3.28 to 226.09). There was a linear increase of VEGF-C expression-weak in CIN1 and intense in CIN3 and SCC (20.49; 8.69 to 48.26). VEGF-C upregulation was a sensitive (93.5%; 95% CI, 90.1% to 96.9%) marker of HR-HPV type (4.70; 2.17 to 10.21), but lost its significance in multivariate regression-p16(INK4a) and survivin were equally strong independent predictors of HR-HPV. Aberrant expression of VEGF-C did not predict clearance/persistence of HR-HPV after treatment of CIN. In cervical cancer, VEGF-C had no prognostic value in univariate or multivariate survival analysis. After adjustment for HR-HPV, FIGO stage, age, and tumour grade, only FIGO stage and age remained independent prognostic predictors. CONCLUSIONS: VEGF-C is an early marker of cervical carcinogenesis, with linearly increasing expression starting from low grade CIN. VEGF-C expression is closely related to HR-HPV in cervical lesions, probably because of its p53 independent upregulation by the E6 oncoprotein of HR-HPV.
AIMS: Increased angiogenesis leads to invasion in cervical cancer. Vascular endothelial growth factors (VEGFs) are involved in angiogenesis, but molecular links to the most important aetiological agent, human papillomavirus (HPV), need clarifying. MATERIAL/ METHODS: Archival samples-150 squamous cell carcinomas (SCCs) and 152 cervical intraepithelial neoplasia (CIN) lesions-were examined immunohistochemically for anti-VEGF-C antibody and for HPV by polymerase chain reaction (PCR). Follow up data were available for all SCC cases, and 67 CIN lesions were monitored with serial PCR to assess HPV clearance/persistence after treatment. RESULTS: High risk (HR) HPV types were closely associated with CIN (odds ratio, 19.12; 95% confidence interval, 2.31 to 157.81) and SCC (27.25; 3.28 to 226.09). There was a linear increase of VEGF-C expression-weak in CIN1 and intense in CIN3 and SCC (20.49; 8.69 to 48.26). VEGF-C upregulation was a sensitive (93.5%; 95% CI, 90.1% to 96.9%) marker of HR-HPV type (4.70; 2.17 to 10.21), but lost its significance in multivariate regression-p16(INK4a) and survivin were equally strong independent predictors of HR-HPV. Aberrant expression of VEGF-C did not predict clearance/persistence of HR-HPV after treatment of CIN. In cervical cancer, VEGF-C had no prognostic value in univariate or multivariate survival analysis. After adjustment for HR-HPV, FIGO stage, age, and tumour grade, only FIGO stage and age remained independent prognostic predictors. CONCLUSIONS:VEGF-C is an early marker of cervical carcinogenesis, with linearly increasing expression starting from low grade CIN. VEGF-C expression is closely related to HR-HPV in cervical lesions, probably because of its p53 independent upregulation by the E6 oncoprotein of HR-HPV.
Authors: B Kleter; L J van Doorn; L Schrauwen; A Molijn; S Sastrowijoto; J ter Schegget; J Lindeman; B ter Harmsel; M Burger; W Quint Journal: J Clin Microbiol Date: 1999-08 Impact factor: 5.948
Authors: K Tokumo; J Kodama; N Seki; Y Nakanishi; Y Miyagi; S Kamimura; M Yoshinouchi; H Okuda; T Kudo Journal: Gynecol Oncol Date: 1998-01 Impact factor: 5.482
Authors: F Karlsen; M Kalantari; A Jenkins; E Pettersen; G Kristensen; R Holm; B Johansson; B Hagmar Journal: J Clin Microbiol Date: 1996-09 Impact factor: 5.948
Authors: M Branca; M Ciotti; D Santini; L Di Bonito; C Giorgi; A Benedetto; P Paba; C Favalli; S Costa; A Agarossi; M Alderisio; K Syrjänen Journal: Int J Gynecol Pathol Date: 2004-10 Impact factor: 2.762
Authors: Carolyn Y Fang; Brian L Egleston; John A Ridge; Miriam N Lango; Dana H Bovbjerg; Jamie L Studts; Barbara A Burtness; Margret B Einarson; Andres J P Klein-Szanto Journal: Head Neck Date: 2013-10-26 Impact factor: 3.147
Authors: M Branca; C Giorgi; M Ciotti; D Santini; L Di Bonito; S Costa; A Benedetto; D Bonifacio; P Di Bonito; P Paba; L Accardi; L Mariani; M Ruutu; C Favalli; K Syrjänen Journal: J Clin Pathol Date: 2006-03-14 Impact factor: 3.411
Authors: Alcina F Nicol; Andréa Rodrigues Cordovil Pires; Simone R de Souza; Gerard J Nuovo; Beatriz Grinsztejn; Aparecida Tristão; Fabio B Russomano; Luciane Velasque; José R Lapa e Silva; Claude Pirmez Journal: BMC Cancer Date: 2008-10-07 Impact factor: 4.430